Howard R. Levin
Fondateur chez Coridea NC1, Inc.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Mark Gelfand | M | - |
Coridea LLC
Coridea LLC Medical SpecialtiesHealth Technology Coridea LLC develops and manufactures medical devices. The firm provides treatment for diastolic heart failure, refractory angina and end-stage renal diseases. The company was founded by Mark Gelfland and Howard R. Levin in 2003 and is headquartered in New York, NY.
Cibiem, Inc.
Cibiem, Inc. Medical SpecialtiesHealth Technology Cibiem, Inc. operates as a medical device company. Its catheter-based approach focuses on carotid body modulation for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes, and renal failure. The company was founded by Mark Gelfand and Howard R. Levin and is headquartered in Los Altos, CA.
Axon Therapies, Inc.
Axon Therapies, Inc. BiotechnologyHealth Technology Axon Therapies, Inc. develops treatment for heart failure. The company is headquartered in New York, NY. | 21 ans |
Paul LaViolette | M | 66 |
Axon Therapies, Inc.
Axon Therapies, Inc. BiotechnologyHealth Technology Axon Therapies, Inc. develops treatment for heart failure. The company is headquartered in New York, NY.
Cibiem, Inc.
Cibiem, Inc. Medical SpecialtiesHealth Technology Cibiem, Inc. operates as a medical device company. Its catheter-based approach focuses on carotid body modulation for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes, and renal failure. The company was founded by Mark Gelfand and Howard R. Levin and is headquartered in Los Altos, CA. | - |
Kenneth Martin | M | - |
Cibiem, Inc.
Cibiem, Inc. Medical SpecialtiesHealth Technology Cibiem, Inc. operates as a medical device company. Its catheter-based approach focuses on carotid body modulation for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes, and renal failure. The company was founded by Mark Gelfand and Howard R. Levin and is headquartered in Los Altos, CA. | 11 ans |
Farhad Khosravi | M | - |
Cibiem, Inc.
Cibiem, Inc. Medical SpecialtiesHealth Technology Cibiem, Inc. operates as a medical device company. Its catheter-based approach focuses on carotid body modulation for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes, and renal failure. The company was founded by Mark Gelfand and Howard R. Levin and is headquartered in Los Altos, CA. | - |
Michael Buck | M | - |
Cibiem, Inc.
Cibiem, Inc. Medical SpecialtiesHealth Technology Cibiem, Inc. operates as a medical device company. Its catheter-based approach focuses on carotid body modulation for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes, and renal failure. The company was founded by Mark Gelfand and Howard R. Levin and is headquartered in Los Altos, CA. | - |
William Hank Kucheman | M | 74 |
Cibiem, Inc.
Cibiem, Inc. Medical SpecialtiesHealth Technology Cibiem, Inc. operates as a medical device company. Its catheter-based approach focuses on carotid body modulation for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes, and renal failure. The company was founded by Mark Gelfand and Howard R. Levin and is headquartered in Los Altos, CA. | 7 ans |
Brian E. Farley | M | 66 |
Axon Therapies, Inc.
Axon Therapies, Inc. BiotechnologyHealth Technology Axon Therapies, Inc. develops treatment for heart failure. The company is headquartered in New York, NY. | 2 ans |
Steve Hochberg | M | 62 |
Axon Therapies, Inc.
Axon Therapies, Inc. BiotechnologyHealth Technology Axon Therapies, Inc. develops treatment for heart failure. The company is headquartered in New York, NY. | - |
Chris H. Colecchi | M | - |
Coridea LLC
Coridea LLC Medical SpecialtiesHealth Technology Coridea LLC develops and manufactures medical devices. The firm provides treatment for diastolic heart failure, refractory angina and end-stage renal diseases. The company was founded by Mark Gelfland and Howard R. Levin in 2003 and is headquartered in New York, NY. | - |
Mitchell S. Bloom | M | - |
Coridea NC1, Inc.
Coridea NC1, Inc. Medical SpecialtiesHealth Technology Coridea NC1, Inc. provides treatment for diastolic heart failure, refractory angina and end-stage renal diseases. The company was founded in 2010 by Howard R. Levin and Mark Gelfand and is headquartered in New York, NY. | - |
Andrew ElBardissi | M | 42 |
Axon Therapies, Inc.
Axon Therapies, Inc. BiotechnologyHealth Technology Axon Therapies, Inc. develops treatment for heart failure. The company is headquartered in New York, NY. | - |
Imran Eba | M | - |
Axon Therapies, Inc.
Axon Therapies, Inc. BiotechnologyHealth Technology Axon Therapies, Inc. develops treatment for heart failure. The company is headquartered in New York, NY. | 10 ans |
Imran Eba | M | - |
Axon Therapies, Inc.
Axon Therapies, Inc. BiotechnologyHealth Technology Axon Therapies, Inc. develops treatment for heart failure. The company is headquartered in New York, NY. | - |
Suraj Mudichintala | M | - |
Axon Therapies, Inc.
Axon Therapies, Inc. BiotechnologyHealth Technology Axon Therapies, Inc. develops treatment for heart failure. The company is headquartered in New York, NY. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
John Erb | M | 75 |
CHF Solutions, Inc. /Old/
CHF Solutions, Inc. /Old/ Medical SpecialtiesHealth Technology CHF Solutions, Inc. is a privately held manufacturer of innovative medical devices for cardiac care and the developer of the aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system. Fluid overload is failure to eliminate excess fluid, primarily salt and water, from the body. While many conditions such as renal failure, metabolic disease and post surgical conditions may result in fluid overload, congestive heart failure is a leading cause. Aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system are designed specifically for use by physicians to safely, effectively, and conveniently treat fluid overloaded patients by removing excess salt and water. With aquaphereis, the physician specifies the amount of fluid to be removed from a patient's blood at a controlled rate and the system does so in a highly controlled and effective way. | - |
John J. O'Mahony | M | - |
CHF Solutions, Inc. /Old/
CHF Solutions, Inc. /Old/ Medical SpecialtiesHealth Technology CHF Solutions, Inc. is a privately held manufacturer of innovative medical devices for cardiac care and the developer of the aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system. Fluid overload is failure to eliminate excess fluid, primarily salt and water, from the body. While many conditions such as renal failure, metabolic disease and post surgical conditions may result in fluid overload, congestive heart failure is a leading cause. Aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system are designed specifically for use by physicians to safely, effectively, and conveniently treat fluid overloaded patients by removing excess salt and water. With aquaphereis, the physician specifies the amount of fluid to be removed from a patient's blood at a controlled rate and the system does so in a highly controlled and effective way. | - |
David B. Springer | M | - |
CHF Solutions, Inc. /Old/
CHF Solutions, Inc. /Old/ Medical SpecialtiesHealth Technology CHF Solutions, Inc. is a privately held manufacturer of innovative medical devices for cardiac care and the developer of the aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system. Fluid overload is failure to eliminate excess fluid, primarily salt and water, from the body. While many conditions such as renal failure, metabolic disease and post surgical conditions may result in fluid overload, congestive heart failure is a leading cause. Aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system are designed specifically for use by physicians to safely, effectively, and conveniently treat fluid overloaded patients by removing excess salt and water. With aquaphereis, the physician specifies the amount of fluid to be removed from a patient's blood at a controlled rate and the system does so in a highly controlled and effective way. | - |
Stephen M. Campe | M | 59 |
CHF Solutions, Inc. /Old/
CHF Solutions, Inc. /Old/ Medical SpecialtiesHealth Technology CHF Solutions, Inc. is a privately held manufacturer of innovative medical devices for cardiac care and the developer of the aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system. Fluid overload is failure to eliminate excess fluid, primarily salt and water, from the body. While many conditions such as renal failure, metabolic disease and post surgical conditions may result in fluid overload, congestive heart failure is a leading cause. Aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system are designed specifically for use by physicians to safely, effectively, and conveniently treat fluid overloaded patients by removing excess salt and water. With aquaphereis, the physician specifies the amount of fluid to be removed from a patient's blood at a controlled rate and the system does so in a highly controlled and effective way. | - |
Kurt C. Wheeler | M | 71 |
CHF Solutions, Inc. /Old/
CHF Solutions, Inc. /Old/ Medical SpecialtiesHealth Technology CHF Solutions, Inc. is a privately held manufacturer of innovative medical devices for cardiac care and the developer of the aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system. Fluid overload is failure to eliminate excess fluid, primarily salt and water, from the body. While many conditions such as renal failure, metabolic disease and post surgical conditions may result in fluid overload, congestive heart failure is a leading cause. Aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system are designed specifically for use by physicians to safely, effectively, and conveniently treat fluid overloaded patients by removing excess salt and water. With aquaphereis, the physician specifies the amount of fluid to be removed from a patient's blood at a controlled rate and the system does so in a highly controlled and effective way. | - |
James M. Garvey | M | 77 |
CHF Solutions, Inc. /Old/
CHF Solutions, Inc. /Old/ Medical SpecialtiesHealth Technology CHF Solutions, Inc. is a privately held manufacturer of innovative medical devices for cardiac care and the developer of the aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system. Fluid overload is failure to eliminate excess fluid, primarily salt and water, from the body. While many conditions such as renal failure, metabolic disease and post surgical conditions may result in fluid overload, congestive heart failure is a leading cause. Aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system are designed specifically for use by physicians to safely, effectively, and conveniently treat fluid overloaded patients by removing excess salt and water. With aquaphereis, the physician specifies the amount of fluid to be removed from a patient's blood at a controlled rate and the system does so in a highly controlled and effective way. | - |
Ronald M. Nelson | M | - |
CHF Solutions, Inc. /Old/
CHF Solutions, Inc. /Old/ Medical SpecialtiesHealth Technology CHF Solutions, Inc. is a privately held manufacturer of innovative medical devices for cardiac care and the developer of the aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system. Fluid overload is failure to eliminate excess fluid, primarily salt and water, from the body. While many conditions such as renal failure, metabolic disease and post surgical conditions may result in fluid overload, congestive heart failure is a leading cause. Aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system are designed specifically for use by physicians to safely, effectively, and conveniently treat fluid overloaded patients by removing excess salt and water. With aquaphereis, the physician specifies the amount of fluid to be removed from a patient's blood at a controlled rate and the system does so in a highly controlled and effective way. | 10 ans |
Steven Brandt | M | 68 |
CHF Solutions, Inc. /Old/
CHF Solutions, Inc. /Old/ Medical SpecialtiesHealth Technology CHF Solutions, Inc. is a privately held manufacturer of innovative medical devices for cardiac care and the developer of the aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system. Fluid overload is failure to eliminate excess fluid, primarily salt and water, from the body. While many conditions such as renal failure, metabolic disease and post surgical conditions may result in fluid overload, congestive heart failure is a leading cause. Aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system are designed specifically for use by physicians to safely, effectively, and conveniently treat fluid overloaded patients by removing excess salt and water. With aquaphereis, the physician specifies the amount of fluid to be removed from a patient's blood at a controlled rate and the system does so in a highly controlled and effective way. | 2 ans |
Ashley Friedman | M | 46 |
CHF Solutions, Inc. /Old/
CHF Solutions, Inc. /Old/ Medical SpecialtiesHealth Technology CHF Solutions, Inc. is a privately held manufacturer of innovative medical devices for cardiac care and the developer of the aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system. Fluid overload is failure to eliminate excess fluid, primarily salt and water, from the body. While many conditions such as renal failure, metabolic disease and post surgical conditions may result in fluid overload, congestive heart failure is a leading cause. Aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system are designed specifically for use by physicians to safely, effectively, and conveniently treat fluid overloaded patients by removing excess salt and water. With aquaphereis, the physician specifies the amount of fluid to be removed from a patient's blood at a controlled rate and the system does so in a highly controlled and effective way. | - |
John R. Wigneswaran | M | - |
CHF Solutions, Inc. /Old/
CHF Solutions, Inc. /Old/ Medical SpecialtiesHealth Technology CHF Solutions, Inc. is a privately held manufacturer of innovative medical devices for cardiac care and the developer of the aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system. Fluid overload is failure to eliminate excess fluid, primarily salt and water, from the body. While many conditions such as renal failure, metabolic disease and post surgical conditions may result in fluid overload, congestive heart failure is a leading cause. Aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system are designed specifically for use by physicians to safely, effectively, and conveniently treat fluid overloaded patients by removing excess salt and water. With aquaphereis, the physician specifies the amount of fluid to be removed from a patient's blood at a controlled rate and the system does so in a highly controlled and effective way. | - |
Ed Rychlick | M | - |
CHF Solutions, Inc. /Old/
CHF Solutions, Inc. /Old/ Medical SpecialtiesHealth Technology CHF Solutions, Inc. is a privately held manufacturer of innovative medical devices for cardiac care and the developer of the aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system. Fluid overload is failure to eliminate excess fluid, primarily salt and water, from the body. While many conditions such as renal failure, metabolic disease and post surgical conditions may result in fluid overload, congestive heart failure is a leading cause. Aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system are designed specifically for use by physicians to safely, effectively, and conveniently treat fluid overloaded patients by removing excess salt and water. With aquaphereis, the physician specifies the amount of fluid to be removed from a patient's blood at a controlled rate and the system does so in a highly controlled and effective way. | - |
Debbie Stephens Ledet | F | - |
CHF Solutions, Inc. /Old/
CHF Solutions, Inc. /Old/ Medical SpecialtiesHealth Technology CHF Solutions, Inc. is a privately held manufacturer of innovative medical devices for cardiac care and the developer of the aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system. Fluid overload is failure to eliminate excess fluid, primarily salt and water, from the body. While many conditions such as renal failure, metabolic disease and post surgical conditions may result in fluid overload, congestive heart failure is a leading cause. Aquapheresis therapy and the Aquadex FlexFlow Fluid Removal system are designed specifically for use by physicians to safely, effectively, and conveniently treat fluid overloaded patients by removing excess salt and water. With aquaphereis, the physician specifies the amount of fluid to be removed from a patient's blood at a controlled rate and the system does so in a highly controlled and effective way. | - |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 26 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Howard R. Levin
- Réseau Personnel